FDA grants Priority Review for Padcev plus Keytruda in muscle-invasive bladder cancer, showing improved survival and reduced ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
FDA grants Priority Review to enfortumab vedotin plus pembrolizumab for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS risk.
Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...
Sichan Kelun-Biotech Biopharmaceutical’s sac-TMT (sacituzumab tirumotecan) has posted positive results in a late-stage trial in non-small cell lung cancer (NSCLC). During the Phase III OptiTROP-Lung05 ...
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results